There are two groups of drugs that target BCR in CLL patients: Bruton’s tyrosine kinase (BTK) inhibitors (BTKis) and phosphoinositide 3-kinase inhibitors (PI3Kis) [9,10]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.